CA3266231A1 - Modulation du gène de translocation de lymphocytes b 1 (btg1) destinée à être utilisée dans une thérapie cellulaire adoptive - Google Patents

Modulation du gène de translocation de lymphocytes b 1 (btg1) destinée à être utilisée dans une thérapie cellulaire adoptive

Info

Publication number
CA3266231A1
CA3266231A1 CA3266231A CA3266231A CA3266231A1 CA 3266231 A1 CA3266231 A1 CA 3266231A1 CA 3266231 A CA3266231 A CA 3266231A CA 3266231 A CA3266231 A CA 3266231A CA 3266231 A1 CA3266231 A1 CA 3266231A1
Authority
CA
Canada
Prior art keywords
btg1
modulation
cell
translocation gene
adoptive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3266231A
Other languages
English (en)
Inventor
Leonid S. Metelitsa
Andras Heczey
Xin Xu
Amy N. Courtney
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of CA3266231A1 publication Critical patent/CA3266231A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3266231A 2022-09-02 2023-08-31 Modulation du gène de translocation de lymphocytes b 1 (btg1) destinée à être utilisée dans une thérapie cellulaire adoptive Pending CA3266231A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263374447P 2022-09-02 2022-09-02
US63/374,447 2022-09-02
PCT/US2023/031654 WO2024049971A2 (fr) 2022-09-02 2023-08-31 Modulation du gène de translocation de lymphocytes b 1 (btg1) destinée à être utilisée dans une thérapie cellulaire adoptive

Publications (1)

Publication Number Publication Date
CA3266231A1 true CA3266231A1 (fr) 2024-03-07

Family

ID=90098639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3266231A Pending CA3266231A1 (fr) 2022-09-02 2023-08-31 Modulation du gène de translocation de lymphocytes b 1 (btg1) destinée à être utilisée dans une thérapie cellulaire adoptive

Country Status (6)

Country Link
EP (1) EP4580641A2 (fr)
JP (1) JP2025529218A (fr)
CN (1) CN120225207A (fr)
AU (1) AU2023334602A1 (fr)
CA (1) CA3266231A1 (fr)
WO (1) WO2024049971A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025217275A2 (fr) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Compositions ciblées sur des cellules immunitaires et procédés associés

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410379D0 (en) * 2004-05-11 2004-06-16 Univ Leicester Treatment of cancer
US20140187604A1 (en) * 2011-05-03 2014-07-03 Dana-Farber Cancer Institute, Inc. Therapeutic and diagnostic target gene in acute myeloid leukemia
WO2016134284A1 (fr) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Récepteurs antigéniques chimériques et leurs utilisations
US11781148B2 (en) * 2017-07-13 2023-10-10 Radici Chimica S.P.A. Biological methods for preparing terpenes
EP3963054A4 (fr) * 2019-05-01 2023-04-26 The Trustees of The University of Pennsylvania Modulation de l'expression de gènes associés à l'épuisement de lymphocytes t
US20240132916A1 (en) * 2021-02-09 2024-04-25 The Broad Institute, Inc. Nuclease-guided non-ltr retrotransposons and uses thereof

Also Published As

Publication number Publication date
JP2025529218A (ja) 2025-09-04
WO2024049971A2 (fr) 2024-03-07
WO2024049971A3 (fr) 2024-04-18
EP4580641A2 (fr) 2025-07-09
AU2023334602A1 (en) 2025-03-27
CN120225207A (zh) 2025-06-27

Similar Documents

Publication Publication Date Title
CA3266231A1 (fr) Modulation du gène de translocation de lymphocytes b 1 (btg1) destinée à être utilisée dans une thérapie cellulaire adoptive
Mueller-Klieser et al. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids
Lund et al. Effect of growth media and serum replacements on the proliferation and differentiation of adipose-derived stem cells
EP2811015B1 (fr) Composition de milieu de culture pour rajeunir des cellules souches
Ivanovic et al. Hypoxia maintains and interleukin-3 reduces the pre–colony-forming cell potential of dividing CD34+ murine bone marrow cells
WO2004096975A3 (fr) Appareil et procedes pour l'amplification du nombre de cellules sanguines souche
Dion et al. Vitamin A-induced density-dependent inhibition of L-cell proliferation
EP1272614A4 (fr) Differentiation des cellules stromales de la moelle osseuse en cellules neuronales et utilisation associee
EP2854824A1 (fr) Utilisation de kératinocytes en tant que substance biologiquement active dans le traitement des plaies, par exemple des plaies diabétiques, facultativement en combinaison avec un inhibiteur de la dpp-4
WO2018217826A1 (fr) Compositions et procédés pour prévenir, ralentir et inverser le vieillissement de la peau
WO2001094541A3 (fr) Cellule souche mesenchymateuse humaine
CA3168116A1 (fr) Utilisation d'activateurs de fgf dans des milieux de culture
Kameyama et al. Treatment of reticulate acropigmentation of Kitamura with azelaic acid: An immunohistochemical and electron microscopic study
RU2382077C1 (ru) Способ выделения и культивирования аутологичных дермальных фибробластов для стимуляции регенеративных процессов и заместительной терапии
Tanaka et al. Immunological abnormality associated with the augmented nitric oxide synthesis in adjuvant-induced arthritis
Bowen et al. Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress?
Nissen et al. Effects of human serum on the release of haemopoietic growth factors
Wang et al. Maresin2 negatively regulates DC’s maturation via the MAPK/NF-κB pathway in DCs
Yang et al. Comparison of prophylactic and preemptive donor lymphocyte infusion in patients with very high risk acute leukemia after allogeneic hematopoietic stem cell transplantation
Charponiere-Rickenberg et al. Zinc levels in zinc-stabilized insulin are inhibitory to the growth of cells in vitro
Wang et al. Differential regulation of inducible nitric oxide synthase gene expression by ethanol in the human intestinal epithelial cell line DLD-1
Lee et al. Mesenchymal stem cells can be obtained from human ACL injury-induced hemathrosis of the knee
Hatta et al. Prerequisite evaluation of anaerobic settings for gut microbiome functional studies
Hu et al. SAT0018 The Study of Cd4+ t Cell Subsets In Recurrent Polychondritis
CN222532568U (zh) 一种用于脐带造血干细胞的冻存管

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250227

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250227

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250227

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250529

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250529

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250529

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250529